Immunocore has filed a patent for T cell receptors that target a specific cancer antigen, PRAME, for immunotherapy. The invention involves modified TCRs that bind to a specific peptide, potentially offering a new treatment option for malignant diseases. GlobalData’s report on Immunocore gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Immunocore Holdings Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Immunocore, Peptide pharmacophores was a key innovation area identified from patents. Immunocore's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Novel t cell receptors for cancer immunotherapy

Source: United States Patent and Trademark Office (USPTO). Credit: Immunocore Holdings Plc

A recent patent application (Publication Number: US20230416335A1) describes a novel heterodimeric TCR-anti-CD3 antibody fusion molecule designed for potential cancer treatment. The molecule consists of a first polypeptide chain containing a TCR alpha chain variable domain and a second polypeptide chain containing a TCR beta chain variable domain. The patent specifies various amino acid sequences for the alpha and beta chain variable domains, along with modifications to the constant domain sequences to enhance the molecule's efficacy.

Furthermore, the patent application includes details about the structure of the TCR-anti-CD3 antibody fusion molecule, such as the single-chain format, linker sequences, and the type of anti-CD3 antibody used. The patent also covers the pharmaceutical composition containing the fusion molecule and its application in treating cancer, particularly in patients with PRAME-expressing cancers like melanoma, lung cancer, breast cancer, and others. The method of treatment involves administering the pharmaceutical composition, potentially through injection, to achieve a therapeutic effect in the human subject with cancer. This patent application represents a significant advancement in the development of targeted cancer therapies utilizing novel fusion molecules.

To know more about GlobalData’s detailed insights on Immunocore, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies